Adicet Bio has laid down a marker for the nascent gamma delta CAR-T cell therapy space, reporting its off-the-shelf candidate ADI-001 triggered responses in a small clinical trial of B-cell non-Hodgkin lymphoma (NHL) patients. Shares in Adicet jumped 45% to above $14 in premarket trading.

Coming in just under the wire to cap off a year filled with outsized medtech special purpose acquisition company deals, BenevolentAI has agreed to combine with SPAC Odyssey in what amounts to Europe’s largest-ever SPAC merger.

Aeglea BioTherapeutics found itself in an unusual position going into the readout from its pivotal rare disease clinical trial. With Aeglea expected to meet its primary endpoint, investors were focused on whether it could show clinical improvement of a secondary measure—and were swift to punish the stock when it fell short of expectations.

Acepodia picked up $109 million to bankroll its pipeline of cell therapies for various cancers, bringing aboard an early Zoom investor in the process.

The U.S. Securities and Exchange Commission (SEC) charged Usama Malik with insider trading during his time as chief financial officer of Immunomedics, a biopharma he helped lead to a $21 billion exit via a Gilead Sciences acquisition last year.

Novartis is betting $150 million on a rival to Parkinson’s disease drugs in development at companies including Roche and AstraZeneca. The deal sees Novartis commit to pay UCB up to around $1.5 billion in milestones for the chance to co-develop a midphase Parkinson’s prospect.

Major U.K. Big Pharma GlaxoSmithKline and leading academic center the University of Oxford have penned a new five-year research collab deal focused on making smarter bets on so-called “digital biology.”

Tune Therapeutics wants in on the rising epigenomic field, spotlighted last month by Chroma Medicine’s $125 million launch. Now, Tune has emerged with $40 million for its own epigenomic controls.

Traditional methods of product planning and launch are evolving in the post-covid-landscape, and all key stakeholders must be reevaluated in order to develop a cohesive strategy. To advance knowledge, stay relevant, and create innovative solutions, it is critical for the industry to come together and share best practices.

A $1.6 billion biobucks pact sounds like a whopping number. But for Dyno Therapeutics, the deal with Astellas Pharma is the latest in a string of partnerships for its gene therapy vectors platform.